279 results
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens
P
1200 participants
I/C
Acupuncture alone, Acupuncture combined with vitamin B, Vitamin B
O
Clinical efficacy
P
pollen, UV-B radiation
I/C
UV-B radiation, pollen germination and tube growth
O
substantial reduction in both pollen germination and tube growth
P
NAFLD participants, controls
I/C
fetuin-A, fetuin-B, compared with controls
O
strength of the association between fetuin-A, fetuin-B, and NAFLD
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
nurses
I/C
health education and counselling, case management and health promotion, running specialist clinics, no intervention
O
increased hepatitis B screening and detection rates, increased odds of hepatitis B virus vaccination, improved immunity rate, enhanced patient adherence to antiviral treatment and monitoring of liver comorbidities
P
pre-menopausal women, post-menopausal women
I/C
B/L oophorectomy, no B/L oophorectomy
O
incidence of Parkinson's disease and parkinsonism
P
breast lesions
I/C
combined shear-wave elastography (SWE) and B-mode ultrasonography (US), B-mode US alone
O
diagnostic performance, biopsy reduction rate, area under the receiver operating characteristic curve (AUC)
P
HBV-infected subjects, uninfected subjects
I/C
ABO blood groups, non-B blood group
O
risk of HBV infection
P
retrovirus, HIV-1, subtypes A, B, C, D
I/C
integration site targeting, evolutionarily divergent retroviruses
O
non-B DNA features, in vivo-derived integration sites, transcriptionally silent regions